ANI Pharmaceuticals (ANIP) has consistently grown revenues and earnings since 2010 both organically and via small acquisitions, but its shares pulled back to as low as around $50 recently after trading north of $70. The stock has since recouped about half of that decline, and I picked up my stake in this promising and fast-growing pharma play at j...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.